摘要
目的探讨注射用盐酸苯达莫司汀治疗利妥昔单抗耐药的B细胞惰性淋巴瘤的临床疗效。方法选取利妥昔单抗耐药的B细胞惰性淋巴瘤患者32例,给予注射盐酸苯达莫司汀,观察并分析患者近期疗效、远期疗效以及不良反应发生情况。结果 32例患者近期疗效总有效率为84.4%;不良反应为骨髓抑制、胃肠道反应和感染;随访2年,患者中位缓解持续时间为10个月,1例患者因疾病进展而病死。结论注射用盐酸苯达莫司汀治疗妥昔单抗耐药的B细胞惰性淋巴瘤患者具有明显疗效。
Objective To investigate the clinical efficacy of B cells of indolent lymphoma of bendamustine hydrochloride for injection in treatment of rituximab resistance in the.Methods 32 B cells in patients with indolent lymphoma were rituximab resistant cases,treated with bendamustine hydrochloride,observe the incidence of longterm and short-term curative effect,curative effect and adverse reaction analysis.Results 32 patients of recent curative effect of the total effective rate was 84.4%,the adverse reactions were bone marrow suppression,gastr-ointestinal reactions and infection.After 2 years of follow-up,the median remission duration of 10 months,because of a short follow-up period,1 patients because of disease progression and death.Conclusion The injection of bendam-ustine hydrochloride monotherapy rituximab resistant B cell indolent lymphoma remarkable curative effect.
出处
《中国药物经济学》
2015年第7期35-36,共2页
China Journal of Pharmaceutical Economics
